CP
INKT icon

Camelot Portfolios’s MiNK Therapeutics INKT Stock Holding History

Camelot Portfolios’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-21
Closed -$195 – 340
2024
Q2 		$195 Buy
+21
New +$204 ﹤0.01% 583

Other funds holding INKT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Camelot Portfolios's INKT Position: Q3 2024 in Review

Camelot Portfolios sold out of MiNK Therapeutics (INKT) in Q3 2024, closing a stake of 21 shares — an estimated $195 sold.

Camelot Portfolios first reported a position in INKT in Q2 2024 and held it in 1 quarter. The position peaked at $195 in Q2 2024. 24 funds tracked by Wall St. Rank hold INKT as of Q3 2024.

  • Camelot Portfolios reported no remaining MiNK Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Camelot Portfolios sold 21 MiNK Therapeutics shares in Q3 2024, an estimated $195.
  • Camelot Portfolios first reported a position in MiNK Therapeutics in Q2 2024 and held it in 1 quarter.
  • Camelot Portfolios's MiNK Therapeutics position peaked at $195 in Q2 2024.
  • 24 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q3 2024.

Based on Camelot Portfolios's 13F filing for Q3 2024, filed 12 Nov 2024.